Clinical Trials Logo

Hypothalamic Obesity clinical trials

View clinical trials related to Hypothalamic Obesity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06239116 Recruiting - Clinical trials for Hypothalamic Obesity

A Study of RM-718 in Healthy Subjects and in Patients With HO

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with hypothalamic obesity (HO).

NCT ID: NCT06217848 Recruiting - Craniopharyngioma Clinical Trials

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Start date: November 28, 2022
Phase: Early Phase 1
Study type: Interventional

GLP-1 analogs are used as agents in the existing treatment of obesity. However, there are lack of previous reports on the effectiveness and role of GLP-1 analogs in the development of obesity traits in patients with functionally impaired hypothalamus. With this preliminary study, the investigators would explore the role of GLP-1 analogues to identify eating behavioral pathology subtype differences in the therapeutic efficacy of GLP-1 analogues in hypothalamic obesity patients. This will allow us to identify the role of specific nuclei which could be the pathogenesis of hypothalamic obesity. Our hypotheses: GLP-1 analogs will effectively induce weight loss in patients with hypothalamic obesity, and different subtypes of hypothalamic obesity will respond differently to GLP-1 analogs.

NCT ID: NCT01783717 Recruiting - Diabetes Mellitus Clinical Trials

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

Start date: December 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of exenatide on body weight and glycemic control in subjects with obesity and/or diabetes mellitus due to hypothalamic damage.